

**LFB Biotechnologies Comments regarding**  
**EC Public Consultation on**  
**the Revision of EU Commission guideline on**  
**Good Manufacturing Practices for Medicinal Products**

**Part I**

**Chapter 6: Quality Control**

LFB Biotechnologies welcomes the opportunity given by the European Commission to comment the draft GMP Part I Chapter 6: Quality Control through a public consultation.

We would like to ask for clarifications. They are submitted within the following table:

<b>Sections</b>	<b>Proposed text</b>	<b>Comments</b>
<i>Sampling</i> 6.12	Samples should be representative of the batch of materials or products from which they are taken. Other samples may also be taken to monitor the most stressed part of a process (e.g. beginning or end of a process). The sampling plan used should be appropriately justified.	We would like some clarifications. What is expected as justification?
<i>Testing</i> 6.20	Reference standards should be certified, qualified and verified as suitable for its intended use.	We would like some clarifications. What is expected as certification and qualification?